(Q60370429)

2 July 2019

title

Chitosan-based nanoparticles for improving immunization against hepatitis B infection. (English)

1 reference

2 July 2019

Africa González Fernández

0 references

0 references

0 references

6

1 reference

2 July 2019

María J. Alonso

7

1 reference

2 July 2019

author name string

Cecilia Prego

1

1 reference

2 July 2019

Patrizia Paolicelli

2

1 reference

2 July 2019

Belen Díaz

3

1 reference

2 July 2019

Sara Vicente

4

1 reference

2 July 2019

Alejandro Sánchez

5

1 reference

2 July 2019

language of work or name

English

0 references

publication date

20 January 2010

1 reference

2 July 2019

published in

Vaccine

1 reference

2 July 2019

volume

28

1 reference

2 July 2019

issue

14

1 reference

2 July 2019

page(s)

2607-2614

1 reference

2 July 2019

The global vaccination gap

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Global health. The new world of global health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Spray-coating for biopharmaceutical powder formulations: beyond the conventional scale and its application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Determinants of release rate of tetanus vaccine from polyester microspheres.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Recent advances in the discovery and delivery of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Needle-free vaccine delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Mucosal vaccines: the promise and the challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

NALT- versus Peyer's-patch-mediated mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Design of biodegradable particles for protein delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Enhancement of nasal absorption of insulin using chitosan nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Polysaccharide colloidal particles as delivery systems for macromolecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

The potential of chitosan for the oral administration of peptides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Virus-like particles: passport to immune recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Pluronic F127-based systemic vaccine delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.011

10.1016/J.VACCINE.2010.01.011

7 January 2021

Identifiers

DOI

1 reference

2 July 2019

1 reference

2 July 2019